Global public relations leader Porter Novelli today announced that it has been named agency of record for the Prix Galien USA Awards, which recognize excellence in biopharmaceutical research and development that has significantly improved the human condition. Porter Novelli will be responsible for raising awareness of the award in the U.S. and driving volume of submissions.
The Prix Galien is internationally renowned for recognizing the development of innovative medicines and medical technologies. Judged by a prestigious committee of scientists and clinicians, the Prix Galien is considered the industry’s highest accolade. The awards are presented in the following categories, in which one to three prizes are given: Best Pharmaceutical Agent, Best Biotechnical Product and Best Medical Device.
“Innovation in medicine is something that needs to be nurtured, acknowledged and rewarded,” said Susan Hayes, global director, health, Porter Novelli. “Porter Novelli is pleased to support the Prix Galien’s commitment to progress in health and medicine, a goal that everyone in the health care community shares.”
The Prix Galien USA award committee comprises 11 individuals including Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals. The 2011 Prix Galien USA Awards will be held on September 27, 2011 at the American Museum of Natural History in New York City.
As part of the events that take place around the awards, Peter Pitts, director of global regulatory and health policy at Porter Novelli, will participate in the panel discussion, “What is ‘Value’ and How Can it be Measured and Demonstrated in Therapeutic Innovations? Breaking Down the Barriers of the Past.”